31
2018-07
Dr. Youzhi Tong of Suzhou Kintor: Entering the Spring for Innovative Drug Development
Dr. Youzhi Tong hopes that Suzhou Kintor is not merely a company that only addresses local pharmaceutical needs,but rather a company with a global product layout.
25
2018-06
Suzhou Kintor’s Dr. Youzhi Tong: In the Name of Father
Aspiring to become an academic expert,Dr. Tong accidentally entered the entrepreneurial circle. Under his leadership,Kintor Pharmaceuticals combines independent research and development with external introductions,develops innovative drug Proxalutamide,and works with Pfizer to develop ALK-1 in an attempt to build a leading anti-tumor innovative drug company in China.
08
2018-05
Proxalutamide Tablet Phase III Clinical Trials Investigator Meeting Was Held Successfully
On May 6, 2018, Proxalutamide Tablet Phase III Clinical Trials Investigator Meeting attracting participation of more than 30 hospitals was successfully held at Hyatt Hotel in Suzhou, symbolizing the official start of the first phase III clinical trials of Suzhou Kintor.
24
2018-01
(January 24, 2018, Suzhou) Suzhou Kintor Pharmaceuticals, Inc. (hereinafter referred to as "Suzhou Kintor") and Pfizer Inc. (“Pfizer”) held a press conference on the development project of innovative antibody drug for cancer in Suzhou today. Under the agreement, Pfizer will grant Suzhou Kintor the exclusive license to develop, produce and commercialize an innovative antibody drug for cancer globally. This is the first time that Pfizer has authorized the license to develop innovative antibody drug to a local Chinese enterprise. The drug is also expected to become the world's first fully human therapeutic monoclonal antibody against Activin receptor-like kinase-1 (ALK-1) target.
11
2018-01
On January 11, 2018, Suzhou Kintor Pharmaceuticals, Inc. ("Suzhou Kintor") announced the completion of Series C investment of RMB 288 million. This round of investment was led by Green Pine Capital Partnership, and followed by Orient Securities Capital Investment, Hangzhou Betta Capital, CCB Investment, and Shanghai Broad Resources, etc.
09
2017-07
2017 Clinical Summit Forum: Where There Is the Market,There Are Clinical Trials | Primary Scene
Dr.Chuangxing Guo of Suzhou Kintor gave a presentation on the implementation of dual declaration of Proxalutamide in China and the United States at the "2017 China Novel Drugs Clinical Development Summit Forum" sponsored by PharmaDJ.Existing data proves that Proxalutamide has obvious advantages in pharmacological activity compared with other AR antagonists,so it is expected to become the best-in-class among the second-generation new AR antagonists.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn